Mostrando 1 - 7 Resultados de 7 Para Buscar 'Moreno, F', tiempo de consulta: 0.05s Limitar resultados
1
artículo
Diversity of Aspergillus isolates and selection of an isolate with high β-fructofuranosidase activity that is native to the Peruvian coast
Publicado por
Gutarra Castillo, Boris, Díez-Municio, Marina, Canchaya Garcia, Susan, Calixto Zacarias, Gaby, Cisneros de la Cruz, Juan, Moreno, F. Javier
Publicado 2017 Enlace
In order to obtain a native isolate with high β-fructofuranosidase activity (FFase), a preliminary selection of 44 isolates, predominantly formed by Aspergillus niger (72%), was performed among 167 isolates of Aspergillus native to the Peruvian coast (Casa grande, Cartavio, Paramonga and Tacama). In addition, genetic diversity was studied using molecular markers, Inter Simple Sequence Repeats (ISSR). The FFase activity of these 44 isolates was compared and the isolate which showed the highest fructosyltransferase (FTase) activity was identified molecularly at the species level by DNA sequencing. Cluster analysis indicated 16 sub-genetic groups of which 11 of them were morphologically identified as Aspergillus niger. Samples from Paramonga showed the highest genetic diversity as explained by the Shannon diversity index (I= 0.21). No positive association was found between the genetic dive...
Agregar a favoritos
Guardado en:
2
artículo
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
Publicado por
Echavarria, I, López-Tarruella, S, Picornell, A, García-Saenz, JÁ, Jerez, Y, Hoadley, K, Gomez, HL, Moreno, F, Monte-Millan, MD, Márquez-Rodas, I, Alvarez, E, Ramos-Medina, R, Gayarre, J, Massarrah, T, Ocaña, I, Cebollero, M, Fuentes, H, Barnadas, A, Ballesteros, AI, Bohn, U, Perou, CM, Martin, M
Publicado 2018 Enlace
Purpose: Triple-negative breast cancer (TNBC) requires the iden- tification of reliable predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the performance of the TNBCtype-4 classifier in a cohort of patients with TNBC treated with neoadjuvant carboplatin and docetaxel (TCb).Methods: Patients with TNBC were accrued in a nonrandomized trial of neoadjuvant carboplatin AUC 6 and docetaxel 75 mg/m2 for six cycles. Response was evaluated in terms of pathologic complete response (pCR, ypT0/is ypN0) and residual cancer burden by Symmans and colleagues. Lehmann's subtyping was performed using the TNBCtype online tool from RNAseq data, and germline sequencing of a panel of seven DNA damage repair genes was conducted.Results: Ninety-four out of the 121 patients enrolled in the trial had RNAseq available. The overall pCR rate was 44.7%. Lehmann sub...
Agregar a favoritos
Guardado en:
3
artículo
International Society of Paediatric Oncology (SIOP) Global Mapping Programme: Latin American Society of Pediatric Oncology (SLAOP) country-level report
Publicado por
Cappellano, A, Gorostegui, M, Gonzalez-Ramella, O, Filho, NPC, Valencia, D, Chantada, L, Sampor, C, Serrano, MJ, Macedo, C, Ramirez, O, Sardinas, S, Lezcano, E, Calderón, P, Gamboa, Y, Fu, L, Gómez, W, Schelotto, M, Ugaz, C, Lobos, P, Aguiar, SDS, Moreno, K, Palma, J, Sánchez, G, Moschella, F, Gassant, PYH, Velasquez, T, Quintero, K, Moreno, F, Villarroel, M, Fuentes, Alabi, S, Vasquez, L, Challinor, J, Chantada, GL
Publicado 2024 Enlace
Background: Latin American countries are improving childhood cancer care, showing strong commitment to implement the Global Initiative for Childhood Cancer, but there are scant publications of the situation at a continental level. Methods: As part of the International Society of Paediatric Oncology Global Mapping project, delegates of each country participating in the Latin American Society of Pediatric Oncology (SLAOP) and chairs of national pediatric oncology societies and cooperative groups were invited to provide information regarding availability of national pediatric cancer control programs (NPCCP), pediatric oncology laws, pediatric oncology tumor registries, and training programs and support to diagnosis and treatment. Results: Nineteen of the 20 countries participating in SLAOP responded. National delegates reported nine countries with NPCCP and four of them were launched in the...
Agregar a favoritos
Guardado en:
4
artículo
International Society of Paediatric Oncology (SIOP) Global Mapping Program: Analysis of healthcare centers in countries of the Latin American Society of Pediatric Oncology (SLAOP)
Publicado por
Gorostegui-Obanos, M, Chantada, L, Filho, NPC, Gonzalez-Ramella, O, Serrano, B, MJ, Valencia, D, Sampor, C, Macedo, C, Ramirez, O, Sardinas, S, Lezcano, E, Calderón, P, Gamboa, Y, Fu, L, Gómez, W, Schelotto, M, Ugaz, C, Lobos, P, Moreno, K, Palma, J, Sánchez, G, Moschella, F, Gassant, PYH, Velasquez, T, Quintero, K, Forteza, M, Villarroel, M, Moreno, F, Alabi, SF, Vasquez, L, Lowe, J, Cappellano, A, Challinor, J, Chantada, GL
Publicado 2024 Enlace
Background: The International Society of Paediatric Oncology Society Global Mapping Program aims to describe the local pediatric oncology capacities. Here, we report the data from Latin America. Methods: A 10-question survey was distributed among chairs of pediatric oncology services. Centers were classified according to patient volume into high- (HVC; 100 or more new cases per year), medium- (MVC; 31–99 cases), and low-volume centers (LVC; 30 cases or less), respectively. National referral centers (NRC) were identified. Results: Total 307 centers in 20 countries were identified (271 responded), and 264 responses were evaluable, accounting for 78% of the expected cases (21,359 cases per year). Seventy-seven percent of patients are treated in public centers, including additional support by civil society organizations. We found that 66% of the patients are treated in 70 centers of excell...
Agregar a favoritos
Guardado en:
5
artículo
Impact of COVID-19 in pediatric oncology care in Latin America during the first year of the pandemic
Publicado por
Villanueva, G, Sampor, C, Palma, J, Villarroel, M, Valencia, D, Lombardi, MG, Garcia, WG, Caceres, EL, Sobrero, V, Garcia, L, Cabrera, V, Maza, I, Velasquez,T, Ugaz, C, Vasquez, JM, Coronado, RD, Gonzalez, N, Aguiar, S, Dabezies A, Moreno, F, Sardinas, S, Gamboa, Y, Maradiegue, E, Fu, L, Gassant, P, Moreno, K, Gonzales, O, Schelotto, M, Luna-Fineman, S, Antoneli, CG, Fuentes-Alabi, S, Luciani, S, Cappellano, A, Chantada, G, Vasquez, L
Publicado 2022 Enlace
Background: The ongoing coronavirus 2019 disease (COVID-19) pandemic strained medical systems worldwide. We report on the impact on pediatric oncology care in Latin American (LATAM) during its first year. Method: Four cross-sectional surveys were electronically distributed among pediatric onco-hematologists in April/June/October 2020, and April/2021 through the Latin American Society of Pediatric Oncology (SLAOP) email list and St Jude Global regional partners. Results: Four hundred fifty-three pediatric onco-hematologists from 20 countries responded to the first survey, with subsequent surveys response rates above 85%. More than 95% of participants reported that treatment continued without interruption for new and active ongoing patients, though with disruptions in treatment availability. During the first three surveys, respondents reported suspensions of outpatient procedures (54.2%), ...
Agregar a favoritos
Guardado en:
6
artículo
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Publicado por
Sharma, P, López-Tarruella, S, García-Saenz, JA, Khan, QJ, Gómez, HL, Prat, A, Moreno, F, Jerez-Gilarranz, Y, Barnadas, A, Picornell, AC, Monte-Millán MD, González-Rivera, M, Massarrah, T, Pelaez-Lorenzo, B, Palomero, MI, González Del Val, R, Cortés, J, Fuentes-Rivera H, Morales, DB, Márquez-Rodas, I, Perou, CM, Lehn, C, Wang, YY, Klemp, JR, Mammen, JV, Wagner, JL, Amin, AL, O'Dea, AP, Heldstab, J, Jensen, RA, Kimler, BF, Godwin, AK, Martín, M
Publicado 2018 Enlace
Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC. Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence of invasive tumor in breast and axilla) and Residual cancer burden (RCB) were evaluated. Patients were followed for recurrence and survival. Extent of pathologic response was associated with RFS and OS using the Kaplan-Meier method. Results: Median age was 51 years, and 52% were node-positive. pCR and ...
Agregar a favoritos
Guardado en:
7
artículo
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
Publicado por
Martín, M, Stecklein, SR, Gluz, O, Villacampa, G, Monte-Millán, M, Nitz, U, Cobo, S, Christgen, M, Brasó-Maristany, F, Álvarez, EL, Echavarría, I, Conte, B, Kuemmel, S, Bueno-Muiño, C, Jerez, Y, Kates, R, Cebollero, M, Kolberg-Liedtke, C, Bueno, O, García-Saenz, JÁ, Moreno, F, Grischke, E-M, Forstbauer, H, Braun, M, Warm, M, Hackmann, J, Uleer, C, Aktas, B, Schumacher, C, Wuerstleins, R, Graeser, M, zu, Eulenburg, C, Kreipe, HH, Gómez, H, Massarrah, T, Herrero, B, Paré, L, Bohn, U, López-Tarruella, S, Vivancos, A, Sanfeliu, E, Parker, JS, Perou, CM, Villagrasa, P, Prat, A, Sharma, P, Harbeck, N
Publicado 2024 Enlace
Background: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of this study was to evaluate the association between TNBC-DX and efficacy outcomes [pathologic complete response (pCR), distant disease-free survival (DDFS) or event-free survival (EFS), and overall survival (OS)] in the validation cohorts. Methods: Information from 1259 patients with early-stage TNBC (SCAN-B, CALGB-40603, and BrighTNess) was used to establish the TNBC-DX scores. Independent validation of TNBC-DX was carried out in three studies: (i) WSG-ADAPT-TN; (ii) MMJ-CAR-2014-01; and (iii) NeoPACT, including 527 patients with stage I-III TNBC undergoing neoadjuvant chemotherapy. In...
Agregar a favoritos
Guardado en: